| Name | Title | Contact Details |
|---|
Calimmune, Inc., a clinical-stage human immunodeficiency virus (HIV) gene medicines company, develops cell-based therapies for HIV. The company offers Cal-1, a gene-based stem cell therapy to protect individuals infected with HIV from progressing to AIDS. It also focuses on developing products to address the needs of various types of individuals at different states of HIV infection and with different levels of treatment experience..
Child Health Corporation of America (CHCA) is a legacy business alliance of children's hospitals. CHCA children's hospitals represented more than 20,000 physicians, 100,000 employees, $14 billion in revenue and $1.8 billion in overall medical, surgical and pharmaceutical products. CHCA's former Owner Hospitals are North America's leading children's hospitals and are widely known for their excellence in caring for America's children. In 2011, CHCA, the National Association of Children's Hospitals and Related Institutions (NACHRI) and its public policy affiliate National Association of Children's Hospitals (N.A.C.H.) merged to pool our strengths and talents, creating a new organization, the Children’s Hospital Association. We share members, a common board of trustees and new President and CEO Mark Wietecha. As one Association, we will continue to be champions for children’s health.
Abortion Advantage is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mercedes Medical Centers is a healthcare provider with a team of doctors, nurses, and caregivers who prioritize patient care and well-being. They have six medical centers located throughout Miami Dade County.
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.